Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for bortezomib mantle cell lymphoma

  1. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA370

  2. Non-Hodgkin's lymphoma: diagnosis and management (NG52)

    This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.

    NICE guideline
    Published
    20 July 2016
    View recommendations

    Sections for NG52

  3. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development Reference number: GID-TA11091 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA833